LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021.
London and Boston, MA, 29 June 2021 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory
Prospectus Publication Announcement
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed pharmaceutical stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.